Inhalation CDMO Industry 2026-2031: Worldwide Growth Driven by Rising Demand for Outsourced Inhalation Drug Development and Manufacturing
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Inhalation CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 2.23 billion in 2025 to USD 2.41 billion in 2026. The market is forecast to reach USD 3.44 billion by 2031, expanding at a compound annual growth rate (CAGR) of 7.54% between 2026 and 2031.
Market growth is being supported by the increasing prevalence of chronic respiratory diseases, rising pharmaceutical outsourcing, advances in particle engineering, and growing demand for combination and connected inhalation devices. Inhalation CDMOs provide specialized development and manufacturing capabilities across metered-dose inhalers, dry-powder inhalers, nebulized formulations, soft-mist inhalers, packaging, labeling, and related services.
Chronic Respiratory Disease Burden Drives Inhalation Therapy Demand
The rising incidence of asthma, chronic obstructive pulmonary disease, and interstitial lung disease continues to increase demand for effective inhaled therapies. The World Health Organization's 2024 update recorded approximately 569.2 million prevalent cases across these respiratory conditions, along with 4.2 million related deaths worldwide.
Disease incidence is increasing rapidly in lower-income regions, where urbanization and deteriorating air quality are contributing to a higher respiratory health burden. Pharmaceutical companies are consequently expanding inhaled drug pipelines beyond conventional bronchodilators to include anti-inflammatory biologics, targeted small molecules, and other advanced therapies.
This shift is creating opportunities for inhalation CDMOs with sub-5-micron particle engineering capabilities, high-potency active pharmaceutical ingredient containment, validated analytical methods, and experience preparing regulatory submissions across multiple jurisdictions. Demand may strengthen further as access to inhalation devices and reimbursement coverage improves in underserved markets.
Pharmaceutical Outsourcing Supports Specialized Manufacturing Growth
Pharmaceutical and biotechnology companies are increasingly outsourcing inhalation drug development and manufacturing to reduce capital requirements and access specialized aerosol expertise. Maintaining propellant filling lines, laser-diffraction testing systems, clean-room infrastructure, and experienced aerosol development teams can be costly, particularly for companies managing intermittent product launches or limited clinical pipelines.
North American and Western European CDMOs continue to secure a significant share of late-stage development and commercial manufacturing contracts due to their regulatory experience, technical infrastructure, and proximity to major pharmaceutical sponsors. Asia-Pacific providers are also expanding their role, particularly in early-stage programs, by offering cost-efficient development and manufacturing services.
Compliance with applicable good manufacturing practice requirements and quality standards remains essential. As qualified capacity stays constrained, established inhalation CDMOs with integrated development, testing, manufacturing, and regulatory capabilities are positioned to benefit from sustained outsourcing demand.
Regulatory Complexity Creates Opportunities and Cost Pressures
Evolving regulatory requirements are increasing development timelines and pre-approval expenses for inhaled products. The U.S. Food and Drug Administration's 2024 draft guidance introduced additional expectations involving real-time stability assessments and aerodynamic testing across multiple flow rates. These requirements may extend development timelines by 12 to 18 months and increase pre-approval costs by as much as 30%.
European regulators have also strengthened dissolution and pharmacokinetic bridging requirements for inhaler device changes. Sponsors pursuing international launches must therefore address multiple regulatory frameworks, including U.S., European, and Japanese requirements. This complexity favors CDMOs with dedicated regulatory teams and quality systems capable of supporting multi-region development programs, although the associated compliance burden can increase operating costs and pressure margins.
Clinical Manufacturing Emerges as a High-Growth Service Segment
Contract development represented 37.09% of inhalation CDMO market revenue in 2025 as sponsors prioritized formulation screening, analytical method development, device selection, feasibility testing, and early regulatory planning. These services can generate stronger margins than routine commercial production because they require specialized expertise and customized development programs.
Clinical manufacturing is expected to record a 10.23% CAGR through 2031, supported by a growing pipeline of Phase II and Phase III respiratory biologics. Investments in spray drying, lyophilization, high-potency handling, and flexible manufacturing technologies are enabling CDMOs to support increasingly complex inhaled products.
Service demand is also moving toward integrated contracts that combine development, clinical manufacturing, commercial production, packaging, labeling, stability testing, and post-approval change management. This model can simplify supplier oversight and help pharmaceutical sponsors maintain consistent product quality throughout the development and commercialization lifecycle.
North America Leads While Asia-Pacific Records the Fastest Growth
North America accounted for 44.25% of global inhalation CDMO market revenue in 2025. Regional leadership is supported by a concentrated respiratory biotechnology sector, mature healthcare reimbursement, advanced manufacturing infrastructure, and the FDA's 505(b)(2) regulatory pathway. Europe also represents a sizable market, benefiting from the European Medicines Agency's centralized procedure for multi-country product launches. Mexico is emerging as a nearshore manufacturing location serving Latin American distribution networks.
Asia-Pacific is projected to expand at an 11.14% CAGR through 2031, making it the fastest-growing regional market. China's accelerated review of generic inhalers and India's production-linked manufacturing incentives are supporting capacity expansion. Japan continues to generate steady demand due to its aging population, while South Korea and Australia are strengthening their positions as clinical trial and pharmaceutical development hubs.
Additional growth opportunities are emerging across the Middle East, Africa, and South America. Long-term expansion in these regions will depend on reimbursement modernization, healthcare investment, currency stability, regulatory development, and broader access to advanced inhalation therapies.
Technological advances in particle engineering, smart inhalers, and combination devices are expected to support continued inhalation CDMO market growth. However, high capital expenditure requirements for aerosol facilities, clean-room integration, specialized testing equipment, and regulatory compliance will remain important constraints through 2031.
Key Topics Covered
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Respiratory Diseases
4.2.2 Pharmaceutical Outsourcing of Specialized Inhalation Manufacturing
4.2.3 Technological Advances in Particle-Engineering and Smart Devices
4.2.4 Growing Adoption of Combination and Smart Inhalers
4.2.5 Low-GWP Propellant Transition Favoring Equipped CDMOs
4.2.6 Surge in Inhalable Biologics and Peptides Pipelines
4.3 Market Restraints
4.3.1 Stringent, Multi-Region Regulatory Compliance Burden
4.3.2 High CAPEX for Aerosol Facilities and Clean-Room Device Integration
4.3.3 Supply Risk for Medical-Grade Propellants During HFC Phase-out
4.3.4 Scarcity of Aerosol Characterization Talent and Test Capacity
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Service Type
5.1.1 Contract Development
5.1.2 Clinical Manufacturing
5.1.3 Commercial Manufacturing
5.1.4 Packaging & Labelling
5.1.5 Other Services
5.2 By Product Type
5.2.1 Metered-Dose Inhalers (MDI)
5.2.2 Dry-Powder Inhalers (DPI)
5.2.3 Nebulized Formulations
5.2.4 Soft-Mist Inhalers (SMI) & Others
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 France
5.3.2.3 United Kingdom
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 India
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.3.5 Australia
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 Aptar
6.3.2 Arcinova
6.3.3 Bend Bioscience
6.3.4 Bespak Limited
6.3.5 Cambrex Corporation
6.3.6 CordenPharma
6.3.7 HCmed Innovations Co., Ltd.
6.3.8 Hovione
6.3.9 Iconovo
6.3.10 Kindeva
6.3.11 Lonza Group AG
6.3.12 Nemera
6.3.13 Novo Holdings A/S (Catalent Inc.)
6.3.14 Recipharm AB (EQT AB)
6.3.15 Ritedose
6.3.16 Sanner GmbH
6.3.17 Siegfried Holding AG
6.3.18 Stevanato Group
6.4 Market Opportunities & Future Outlook
6.4.1 White-Space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/44wzg7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.